Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study

作者：Gerds AT, Fan Q, Jerry M, Cerretani A, Tran AT, Hernandez L · 发表于：Journal of blood medicine · 年份：2026 · DOI：10.2147/jbm.s626464 · 被引用次数：40 · 研究领域：cytoreductive therapy、hematocrit control、phlebotomy、thromboembolic event、thrombotic event

PURPOSE: To evaluate treatment and disease burden among patients with polycythemia vera (PV) receiving the current standard of care (SoC) in the US. PATIENTS AND METHODS: This retrospective study utilized MarketScan® Commercial/Medicare Databases to identify patients with PV diagnosis and treatment claims between 1/1/2011-12/31/2022 (index date=earliest PV treatment date), continuous enrollment (6 months pre-index and ≥12 months post-index), and no pre-index disease progression (myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome). Patients were categorized by thrombosis risk (high/low-risk) and 12-month post-index treatments: phlebotomy (PHL) only, hydroxyurea (HU) only, PHL+HU, or ruxolitinib/interferons (RUX/IFN). Outcomes included incident TE, iron deficiency anemia, disease progression, and PV-related symptoms. Hematocrit (HCT) control was evaluated in patients with ≥2 HCTs post-index (HCT analysis). All-cause costs during the 12 months post-TE were reported in patients with an incident TE and ≥12 months post-TE follow-up (TE analysis). RESULTS: Among 11,311 patients (51.8% high-risk; 48.2% low-risk; median follow-up ~2.8 years), 12-month post-index treatments included PHL only (75.0%), HU only (12.2%), PHL+HU (10.9%), and RUX/IFN (1.9%). Frequent PHL (≥3 PHL in 6 months or ≥5 PHL in 12 months post-index; 46.2% of PHL users) and high-dose HU (≥1000mg/day; 41.7% of HU users) were common. Within 12 months post-index, 50.9% of patients experienced burdensom...